跳至主要内容
临床试验/CTRI/2012/05/002669
CTRI/2012/05/002669Other未知

Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients - MultiSENSE

Guidant Europe a Boston Scientific Company0 个研究点目标入组 990 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
Other
发起方
入组人数
990

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • •1. Age 18 or above, or of legal age to give informed consent specific to state and national law.
  • •2. Willing and capable of returning for all follow-up visits and emergency care at the investigational center as medically appropriate.
  • •3. Willing to participate in all testing associated with this clinical investigation at an approved clinical investigational center.
  • •4. Currently implanted with a CRT-D system including a COGNIS device (model N119, N120, P107 or P108) with RA, RV and LV leads
  • •5. Currently classified as NYHA Class II, III or IV within the last six months

排除标准

  • •1. Inability or refusal to sign the Subject Informed Consent.
  • •2. Inability or refusal to comply with the follow-up schedule.
  • •3. Documented as pacemaker dependent.
  • •4. Unable to rest comfortably in a semi-recumbent position for up to 20 minutes.
  • •5. Implanted with active Medtronic Fidelis lead models: 6930, 6931, 6948 or 6949.
  • •6. Currently implanted with unipolar RA, RV, or LV leads.
  • •7. LV sensitivity programmed to less than 0.7 mV AGC.
  • •8. Subjects that have a history of appropriate Tachycardia Therapy (external or implanted) for rates 165 bpm within 1 week prior to enrollment.
  • •9. Device battery status indicates approximate time to explant 2 years.
  • •10. Likely to undergo lead or PG revision during the course of the study as determined by the investigator.
  • •11. Receiving regularly scheduled intravenous (IV) inotropic therapy as part of their drug regimen.
  • •12. Subjects that have received a heart or lung transplant.
  • •13. Receiving mechanical circulatory support.
  • •14. Subjects who have been referred or admitted for Hospice care.
  • •15. A life expectancy of less than 12 months per physician discretion.
  • •16. Enrolled in any concurrent study without Boston Scientific written approval.
  • •17. Subjects whose devices have previously been converted to the SRD-1 and withdrawn from this study.
  • •18. Subjects who have received a sub-pectoral COGNIS implant prior to February 1st 2011 that has a dash number listed in APPENDIX K.
  • •19. Women who are known to be pregnant or plan to become pregnant within the course of the study.
  • •20. LV offset is programmed to a value greater than zero

研究者

发起方
Guidant Europe a Boston Scientific Company

相似试验